You may find more results for this query on our sister sites: GenomeWeb and 360Dx.
News on molecular markers used to guide cancer treatment, assess prognosis, or detect relapse.
Results of the Phase II monarcHER study suggest that heavily pretreated HER2-positive breast cancer patients may be spared a chemotherapy-based regimen.
Under this agreement, Bixink will be responsible for seeking regulatory approval for Nerlynx in South Korea, and Puma could receive payments of up to $6 million from drug sales.
At AACR's annual meeting, a researcher described how the breakthrough therapy designated drug was designed specifically to overcome the challenges of targeting EGFR exon 20 insertions.
The drugmaker will promote Zejula without a biomarker as a first-line maintenance option, and Myriad will highlight that patients with HRD are most likely to benefit.
WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.
Additional analyses found the talazoparib arm reported a better quality of life and a limited effect of broader tumor genomic markers on clinical benefit or progression-free survival.
RemeGen's anti-HER2 antibody drug conjugate disitamab vedotin already achieved an overall response rate of 60 percent in a Phase II trial conducted in China.
In two studies, researchers showed the benefit of combining Tecentriq, Cotellic, and Zelboraf and sticking with continuous versus intermittent dosing of targeted drugs.
Though the Phase II results from the I-SPY 2 trial showed a potential benefit of the regimen in the neoadjuvant setting, additional data are needed.
Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.